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Alterations in global DNA methylation have been associated with oxidative stress (OS). Since 
chronic obstructive pulmonary disease (COPD) is characterized by increased oxidative stress we 
aimed to evaluate the levels of global DNA methylation in this patient group.  
Methods  
We assessed methylcytosine (mCyt) levels in DNA from blood collected in 43 COPD patients (29 
with mild and 14 with moderate disease) and 43 age-nd sex-matched healthy controls.  
Results  
DNA methylation was significantly lower in COPD patients vs. controls (4.20±0.18 % mCyt vs. 
4.29±0.18 % mCyt, p=0.02). Furthermore, DNA methylation in COPD patients with moderate 
disease was significantly lower than that in patients with mild disease (4.14 ± 0.15 % mCyt vs. 
4.23±0.19 % mCyt, p<0.05). Univariate logistic regrssion analysis showed that lower DNA 
methylation levels were associated with presence of COPD (crude OR=0.06, 95% CI 0.00 to 0.67, 
p=0.023). This relationship remained significant after adjusting for several confounders (OR 0.03, 
95% CI 0.00 to 0.67; p=0.028). Receiver operating characteristics (ROC) curve analysis 
demonstrated the area under the curve of mCyt was 0.646, with 46.6% sensitivity and 79.1% 
specificity for presence of COPD.  
Conclusions  
There were no significant correlations between methyla ion and OS indices. The presence and 
severity of COPD is associated with progressively lower DNA methylation in blood. However, this 
epigenetic alteration seems independent of oxidative stress. 
 

















Epigenetics refers to various processes that modify the functionality of genome under exogenous 
stimuli, and also provide a molecular mechanism that allows a stable transmission of gene 
expression states to the next generation of cells [3]. Methylation of DNA cytosines of dinucleotide 
sequence CpG is an epigenetic mechanism involved in the regulation of gene expression and 
cellular differentiation [1-2]. The methyl donor for this reaction is S-adenosylmethionine (SAM) 
whereas the addition of the methyl group is catalyzed by one of the three active DNA 
methyltransferases; DNMT1 [4], DNMT3a, or DNMT3b [5]. DNMT1 is generally responsible for 
copying the methylation pattern from the parent strand to the daughter strand during DNA 
replication [4], while DNMT3A/B exhibit de novo activity during cellular transitions [5]. The 
inclusion of a methylated cytosine within a regulatory element can prevent transcription factors 
from binding the DNA in some occurrences, which in turn limits transcription at that locus [6]. 
Thus, normally DNA hypomethylation is associated with gene transcriptional activity while 
hypermethylation is related to gene silencing. Previous studies support a role for DNA methylation 
in some diseases such as cancer and cardiovascular dise se [7-8]. Furthermore, there is evidence 
that, in these disease states, global DNA methylation is strictly related to oxidative stress [7-10]. 
Oxidative stress occurs when reactive oxygen species (ROS) production in the body exceeds the 
defense mechanisms conferred by protective anti-oxidants, leading to oxidative attack on cellular 
structures such as DNA. Transient increases in oxidative bout lead to the generation of DNA base 
adducts, such as 8-hydroxyl-2′-deoxyguanosine (8-OH-dG) and O6-methylguanine, that strongly 
inhibit methylation of adjacent cytosine residues, ultimately leading to global DNA 
hypomethylation [11]. Moreover, it has been reported that a more oxidized cellular redox state may 
lead to a decrease in genomic DNA methylation through redox regulation of related enzymes. In 
particular, the presence of cysteine residues has led to the identification of the SAM-dependent 
methyltransferases as potentially redox-sensitive enzymes [12]. Furthermore, the activity of 














for the synthesis of SAM, is decreased in a more oxidized environment [13]. In consideration of the 
metabolic link between alterations in DNA methylation and oxidative stress we assessed global 
DNA methylation in chronic obstructive pulmonary disease (COPD), a chronic condition 
characterized by increased local and systemic oxidative stress. In particular, we tested the 
hypothesis that a) DNA methylation is associated with COPD presence and severity and b) DNA 
methylation is associated with OS markers. 
Methods 
Subjects  
This was a case–control study of 43 patients with COPD (mean age 74.8±5.9 years, range 52-85 
years), with mild or moderate form of disease recently diagnosed according to pre-defined clinical 
criteria, and 43 sex- and age matched healthy controls. All subjects were recruited from the 
Respiratory Unit of the University of Sassari. COPD patients with significant symptom 
deterioration, indicative of disease exacerbation, within the last three months were not enrolled. 
None of the selected patients had a previous diagnosis of COPD, took inhaled corticosteroids within 
four weeks prior to the study, or was on long- or short-acting β- agonists or long-acting muscarinic 
antagonists at the time of the assessments. Each patient underwent physical examination, chest 
radiographs, routine blood tests, and respiratory function tests. The latter included forced vital 
capacity (FVC), forced expiratory volume in 1 sec (FEV1) and FEV1/FVC. A structured 
questionnaire was administered to collect clinical and demographic data, including age, body mass 
index (BMI), occupation and smoking status.  
COPD diagnosis and severity was assessed according to a patient’s smoking history, physical 
examination, respiratory symptoms, and spirometric results based on the Global Initiative for 
Chronic Obstructive Lung Disease criteria [14]. Diagnosis of COPD required confirmation of 
airflow limitation that is not fully reversible (post-bronchodilator FEV1/FVC ratio <0.7). 














Controls were selected from general population. Exclusion criteria for controls included the 
presence of concomitant inflammatory disease such as autoimmune disorders and infections, 
cancer, liver, kidney and heart disease. Also controls completed a structured questionnaire and 
underwent physical examination, routine blood tests and respiratory function tests. 
This study was approved by the Institutional Local Ethics Committee (Azienda Sanitaria Locale n°1 
di Sassari (Italy) (prot. 2175/CE del 21/04/2015), and was in accordance with the principles of 
Declaration of Helsinki. All subjects provided written informed consent. 
Biochemical analysis 
Whole blood DNA methylation was determined as follows. Genomic DNA extraction was 
performed by using QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA) according to the 
instructions supplied by the manufacturer. The purified DNA was then hydrolyzed by 90% formic 
acid. After hydrolysis, samples were evaporated and the dry residue containing free bases was 
dissolved in ultrapure water and immediately analyzed by capillary electrophoresis as described 
previously [15]. The percentage of methylated to total cytosine (mCyt/tCyt) was calculated using 
the formula: {[mC] / [mC] + [C]}*100. The inter-assay CV for mCyt/tCyt measurements was 3.3%. 
Plasma PSH determination was performed by spectrophot metry with 5,5'-dithiobis-2-nitrobenzoic 
acid (DTNB) as titrating agent by measuring the absor ance of conjugate at 405 nm [16]. 
Concentration in samples was determined from a GSH standard curve. PSH refers to total protein 
sulfhydryl groups in plasma. The most abundant reduc  -SH group in plasma is that of albumin 
Cys34 that accounts for about 80% of all reduced thiols n human plasma. It is an important 
scavenger of reactive oxygen and nitrogen species in the vascular compartment and then a 
significant redox buffer system of blood [17]. In presence of oxidative stress the –SH groups of 
proteins become oxidized to disulfide or sulfenic acid, leading to a reduction in –SH groups. 
TBARS were determined according to the method described by Esterbauer and Cheeseman [18]. 
TBARS assay measures malonyldihaldehyde (MDA) and other aldehydes produced as a result of 














thiobarbituric acid yielding a product that can be detected spectrophotometrically by measuring the 
absorbance at 535 nm. A calibration curve was obtained using standard MDA. The measurement of 
TBARS is a well-established method for screening and monitoring lipid peroxidation [19]. 
Statistical analysis 
All results are expressed as mean values (mean ± SD) or median values (median and range). 
Variables distribution was assessed by the Kolmogorov-Simirnov test. Statistical differences 
between groups were compared using unpaired Student’s t-test or Mann-Whitney rank sum test, as 
appropriate. Correlation analysis between variables wa  performed by Pearson's correlation or 
Spearman’s correlation as appropriate. Multiple comparisons were performed by one-way ANOVA. 
Levene's test for equality of error variances was employed, while student-Newman-Keuls test for all 
pairwise comparisons was used. Non-normally distribu ed variables were log10-transformed prior 
to being used with parametric tests. Normal distribu ion of the residuals was checked to assess the 
goodness of fit of the transformations. 
Logistic regression analysis with COPD absence vs. presence as dependent variable was performed 
to determine independent associations between variables potentially involved in disease 
development. 
A further logistic regression analysis with mild or moderate condition as dependent variable was 
conducted to determine associations between COPD severity and variables potentially involved in 
disease progression. 
The ability of global DNA methylation to discriminate COPD versus controls was analyzed using 
receiver operating characteristics (ROC) curve analysis. Optimal cutoff maximizing sensitivity and 
specificity was selected. Sensitivity and specificity were reported using the optimal ROC curve 
value according to the Youden Index. 
Statistical analyses were performed using MedCalc for Windows, version 15.4 64 bit (MedCalc 
Software, Ostend, Belgium) and SPSS for Windows, version 14.0 32 bit (IBM Corporation; 















Table 1 reports demographic and clinical characteristics of controls and COPD patients. As 
expected, COPD patients showed a reduced FEV1 (2.02±0.59 L vs. 2.75±0.59 L, p<0.0001), FVC 
(2.94 ± 0.78 L vs. 3.40 ± 0.73 L, p<0.01) and FEV1/FVC ratio (68.4±5.7 vs. 80.8 ± 4.9, p<0.001) 
when compared with controls. There were no between-group differences in smoking status or BMI. 
As expected, COPD patients with moderate disease sev rity had a lower FEV1 (1.56±0.32 L vs. 
2.24±0.56 L, p<0.0001), FVC (2.44 ± 0.54 L vs. 3.18 ± 0.77,  p<0.01) and FEV1/FVC ratio 
(64.8±5.7 vs. 70.2±4.9, p<0.01) when compared with patients with mild disease (Table 2). The 
distribution plots of global DNA methylation, reported in figure 1, show a lower degree of 
methylation in COPD patients (range 3.88-4.67 % mCyt; IQR 4.04-4.48 % mCyt) when compared 
with controls (range 3.98-4.69 % mCyt; IQR 4.18-4.40 % mCyt). Furthermore, as reported in figure 
2, DNA methylation was significantly lower in COPD patients than in controls (4.20±0.18 % mCyt 
vs. 4.29±0.18 % mCyt, p=0.02). A significant trend towards lower DNA methylation was observed 
according to COPD presence and severity (p=0.018, Figure 3). Furthermore, patients with moderate 
disease had significantly lower DNA methylation than patients with mild disease (4.14±0.15 % 
mCyt vs. 4.23±0.19 % mCyt, p<0.05). As previously reported [20], TBARS concentrations 
significantly increased, and PSH concentrations significantly decreased, according to COPD 
presence and severity. However, no significant correlations were observed between global DNA 
methylation and oxidative stress indices. In univariate logistic regression, lower DNA methylation 
levels were independently associated with presence of COPD (crude OR=0.06, 95% CI 0.00 to 
0.67, p=0.023). This association remained significant lso after adjusting for age, sex, BMI, 
smoking status, and oxidative stress indices (OR 0.03, 95% CI 0.00–0.67; p=0.028).   
In ROC curve analysis, evaluating the sensitivity, specificity, and diagnostic accuracy of DNA 
methylation degree in distinguishing COPD from healthy subjects, % mCyt with a threshold of 4.15 
discriminated COPD from controls with 46.6% sensitivity and 79.1% specificity (AUC=0.646, 95% 














A multiple logistic regression analysis on 43 COPD patients according to disease severity (mild vs. 
moderate), after adjusting for the abovementioned parameters, showed that lower global DNA 
methylation was independently associated to more advanced disease (OR 0.00, 95% CI 0.00-0.78, 
p=0.043). Multiple logistic regression analysis of mild COPD patients vs. controls showed a trend 
towards significant associations between global DNA methylation and mild COPD (OR 0.06, 95% 
CI 0.00-1.67, p=0.098). 
Discussion 
A central role in the pathophysiology of COPD is played by the chronic inflammation of the small 
and distal airways. This is characterized by a significant increase in the number of activated 
neutrophils and macrophages, inflammatory mediators [21-22] and anion superoxide (O2·-), 
probably through an impairment of the nicotinamide adenine dinucleotide phosphate oxidase 
pathway. In addition, hypoxaemia, a common feature in COPD, may induce a reduction in 
haemoglobin oxygen saturation levels, resulting in local tissue hypoxia [23]. Experimental studies 
suggest that hypoxaemia enhances oxidative stress in COPD, probably through the increase of ROS 
production at the respiratory chain level of mitochndria [24-25]. It has been proposed that in 
COPD the increased oxidant burden may not be adequately counterbalanced by the lung antioxidant 
systems, resulting in oxidative stress. Although the pathogenesis of COPD remains unclear, the 
central role of oxidative stress is well established [20, 26-27]. Oxidative stress adversely affects 
cellular functions, since excessive quantity of ROS leads to protein, lipids, and DNA damage [28]. 
In addition, it has been reported that oxidative stress may be associated with a DNA 
hypomethylation pattern through several mechanisms, involving guanine hydroxylation in CpG 
dinucleotides (thus generating 8-OH-dG that inhibit proximal cytosine methylation) or reduced 
activity of the redox sensitive enzymes SAM-dependent methyltransferases [11-12]. Moreover, it 
has been postulated that GSH depletion during chronic xidative stress may lead to decreased 














support of this hypothesis, treatment with the GSH-depleting hepatotoxin bromobenzene has been 
reported to induce extensive depletion of methionine levels and DNA hypomethylation in the liver 
of Syrian hamsters [30]. Niedzwiecki et al. [9] recently reported that a more oxidized blood GSH 
redox status is associated with decreased global DNA methylation in peripheral blood mononuclear 
cell. However, blood SAM does not appear to mediate this association. In addition, a study of 45 
infertile men showed that seminal ROS production was negatively correlated with sperm global 
DNA methylation. In this study, a three-month supplementation with antioxidants significantly 
reduced seminal ROS, increasing sperm global DNA methylation [31]. Therefore, we tested the 
hypothesis that the increased oxidative stress in COPD may lead to alterations in global DNA 
methylation. This hypothesis was confirmed by the observation of significantly lower DNA 
methylation indexes in patients with COPD vs. healthy controls. A further reduction in DNA 
methylation was associated with disease progression. N tably,  logistic regression analysis showed 
that the degree of DNA methylation was independently associated with COPD after adjusting for 
key demographic and clinical confounders, and oxidative stress indices. A cut-off value of 4.15 for 
the % mCyt determined on the ROC curve yielded the best sensitivity (46.6%) and specificity 
(79.1%) towards COPD presence. Further logistic regression analyses showed significant 
associations between DNA methylation and disease sev rity in COPD patients and a trend towards 
significant associations between DNA methylation and early COPD disease in healthy controls and 
COPD patients with mild disease. This suggests that DNA methylation is primarily involved in 
disease progression, when oxidative stress is more arked. However, contrary to this hypothesis, 
we observed no significant correlations between global DNA methylation and oxidative stress 
indices. It is likely that this might be due to the relatively small study population and/or the absence 
of patients with severe or unstable form of the disease, likely to be characterized by a particularly 
high oxidative stress. Therefore, it would be interesting to evaluate associations between DNA 
methylation and oxidative stress indices in patients with more severe symptoms (COPD stages 3 














methylation values showed a relatively narrow distribution, with a ratio between the inter-quartile 
difference and the median of 0.05, suggesting a particularly low biological variation (inter-
individual CV 4.2%). This might reduce the likelihood of identifying strong associations between 
methylation levels and other biochemical or clinical v riables, particularly when the inter-assay CV 
was above the defined threshold values for the sample size analyzed [32].   
Conclusions 
The present study demonstrates for the first time that global DNA methylation indexes are 
independently associated with COPD in patients with stable disease. Further studies, with a larger 
sample size, also including those with more severe symptoms, are required to elucidate the 
relationship between DNA mCyt levels and oxidative stress, and to fully characterize the impact of 
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Figure 1. Distribution plots of % mCyt  in control subjects and COPD patients. The biological 
variation expressed as inter-individual CV was respectively 4.2 and 4.5% and the ratio between the 
inter-quartile difference and the median was respectiv ly 0.05 and. 0.06. 
Figure 2. % of mCyt in DNA extracted from blood in healthy subjects (n=43) and in all COPD 
patients (n=43). The central horizontal line on each box represents the median, the ends of the 
boxes are 25 and 75 percentiles and the error bars 5% and 95%. P-values derived from Student-
Newman-Keuls test. 
Figure  3. % of mCyt in DNA extracted from blood in healthy subjects (n=43) and in COPD 
patients after sorting in mild (n=29) and moderate disease (n=14). The central horizontal line on 
each box represents the median, the ends of the boxs are 25 and 75 percentiles and the error bars 
5% and 95%. P-values derived from Student-Newman-Keuls t st. 













Table 1. Characteristic features of the study groups. 





Subjects, n 43 43  
Age (years) 73.4±6.9 74.8±5.9 NS 
Males, n 34 34 NS 
BMI (kg/m2) 26.4±3.6 27.4±3.7 NS 
Lung function 
FEV1 (L) 2.75±0.59 2.02±0.59 <0.001 
FEV1 (% predicted) 112.1±14.4 80.1±17.8 <0.001 
FVC (L) 3.40±0.73 2.94±0.78 <0.01 
FVC (% predicted) 107.9±15.4 88.0±15.2 <0.001 
FEV1/FVC (%) 80.4±3.9 66.6±4.8 <0.001 
RV (L) 3.07±0.6 3.42±0.9 NS 
RV (% predicted) 125.4±22.4 137.3±32.5 NS 
TLC (L) 6.6±1.1 6.4±1.1 NS 
TLC (% predicted) 110.3±13.8 107.8±14.4 NS 
RV/TLC (%) 46.8±5.6 53.4±8.7 <0.001 
Smoking status 
Current smokers  3 (7%) 3 (7%) NS 
Never smoked 14 (32.6%) 10 (23.2) NS 
Ex-smokers 26 (60.4%) 30 (69.8%) NS 
FEV1: Forced Expiratory Volume in the 1st second; FVC: Forced Vital Capacity; 













Table 2. Clinical and functional characteristics of mild versus moderate COPD patients 





Subjects, n 29 14  
Age (years) 75.4±4.8 73.4±7.7 NS 
Males, n 22 12 NS 
BMI (kg/m2) 27.4±3.4 27.4±4.5 NS 
Lung function 
FEV1 (L) 2.24±0.56 1.56 ± 0.32 <0.001 
FEV1 (% predicted) 92.8±6.9 62.7±12.2 <0.001 
FVC (L) 3.18±0.77 2.44±0.54 <0.01 
FVC (% predicted) 97.9±5.3 74.7±14.0 <0.001 
FEV1/FVC 68.6±1.4 63.4±6.5 <0.001 
RV (L) 3.10±0.55 3.85±1.07 0.025 
RV (% predicted) 127.3±26.0 150.8±36.4 0.02 
TLC (L) 6.26±0.89 6.55±1.38 NS 
TLC (% predicted) 108.9±10.6 106.3±18.4 NS 
RV/TLC (%) 49.9±8.0 58.2±7.3 <0.001 
Smoking status 
Current smokers  2 (6.9 %) 1 (7.1%) NS 
Never smoked 8 (27.6%) 2 (14.2%) NS 
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